| 新发重大传染病的临床治疗药物应对：超说明书用药与同情用药 |
| 投稿时间：2020-03-07 修订日期：2020-04-27 点此下载全文 |
| 引用本文：李竺蔓,郭芷君,徐峰.新发重大传染病的临床治疗药物应对：超说明书用药与同情用药[J].药学实践杂志,2020,38(3):207~210 |
| 摘要点击次数: 770 |
| 全文下载次数: 737 |
|
| 基金项目:上海市临床药学重点专科建设项目（2018—2020） |
|
| 中文摘要:目前，由新型冠状病毒(SARS-CoV-2)导致的肺炎(COVID-19)尚无针对性治疗药物，临床主要选择干扰素、洛匹那韦/利托那韦、利巴韦林、磷酸氯喹、阿比多尔等超说明书用药和瑞德西韦同情用药。为此，对这两种临床用药应对行为给予评述。 |
| 中文关键词:治疗药物应对 新发重大传染病 超说明书用药 同情用药 |
| |
| Clinical medication response under new major infectious disease: off-label use and compassionate use |
|
|
| Abstract:At present, there are no specific targeted drugs for the treatment of pneumonia (COVID-19) caused by the novel coronavirus (SARS-CoV-2). Interferon, lopinavir/ritonavir, ribavirin, chloroquine phosphate were chosen as off-label use, and remdesivir was chosen as compassionate use. This paper reviewed the behavior of the two medication response to the new major infectious disease. |
| keywords:medication response new major infectious disease off-label use compassionate use |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
